现代泌尿生殖肿瘤杂志
現代泌尿生殖腫瘤雜誌
현대비뇨생식종류잡지
JOURNAL OF CONTEMPORARY UROLOGIC AND REPRODUCTIVE ONCOLOGY
2014年
4期
214-216
,共3页
刘波%潘铁军%蔡莹%文瀚东%沈国球%涂忠%钱卫红%杨家荣
劉波%潘鐵軍%蔡瑩%文瀚東%瀋國毬%塗忠%錢衛紅%楊傢榮
류파%반철군%채형%문한동%침국구%도충%전위홍%양가영
高危非肌层浸润性膀胱癌%等离子电切术%膀胱灌注%沙培林
高危非肌層浸潤性膀胱癌%等離子電切術%膀胱灌註%沙培林
고위비기층침윤성방광암%등리자전절술%방광관주%사배림
High risk%Nonmuscle invasive bladder cancer%Transurethral plasmakinetic resection%Intravesical instillation%Picibanil
目的:探讨经尿道等离子电切术联合沙培林膀胱灌注治疗高危非肌层浸润性膀胱癌的疗效。方法选取本院2010年6月至2013年1月收治的50例高危非肌层浸润性膀胱癌患者,均采用经尿道等离子电切术,术后1周开始定期行沙培林(5 KE)膀胱灌注,观察疗效。结果平均手术时间(30.38±3.2)min,术中出血量较少,无膀胱穿孔。所有患者随访6~24个月,中位时间14.8个月,肿瘤复发率为8%,并发症发生率为20%。结论经尿道等离子电切术与沙培林膀胱灌注联合治疗高危非肌层浸润性膀胱癌的疗效确切,安全性高,值得推广。
目的:探討經尿道等離子電切術聯閤沙培林膀胱灌註治療高危非肌層浸潤性膀胱癌的療效。方法選取本院2010年6月至2013年1月收治的50例高危非肌層浸潤性膀胱癌患者,均採用經尿道等離子電切術,術後1週開始定期行沙培林(5 KE)膀胱灌註,觀察療效。結果平均手術時間(30.38±3.2)min,術中齣血量較少,無膀胱穿孔。所有患者隨訪6~24箇月,中位時間14.8箇月,腫瘤複髮率為8%,併髮癥髮生率為20%。結論經尿道等離子電切術與沙培林膀胱灌註聯閤治療高危非肌層浸潤性膀胱癌的療效確切,安全性高,值得推廣。
목적:탐토경뇨도등리자전절술연합사배림방광관주치료고위비기층침윤성방광암적료효。방법선취본원2010년6월지2013년1월수치적50례고위비기층침윤성방광암환자,균채용경뇨도등리자전절술,술후1주개시정기행사배림(5 KE)방광관주,관찰료효。결과평균수술시간(30.38±3.2)min,술중출혈량교소,무방광천공。소유환자수방6~24개월,중위시간14.8개월,종류복발솔위8%,병발증발생솔위20%。결론경뇨도등리자전절술여사배림방광관주연합치료고위비기층침윤성방광암적료효학절,안전성고,치득추엄。
Objective To investigate the effect of intravesival instillation of picibanil in the prophylaxis of local recurrence after transurethral plasmakinetic resection of high risk nonmuscle in-vasive bladder cancer(NMIBC). Methods 50 patients of high risk NMIBC in our hospital during June 2010 to January 2013 were choosed randomly to be treated with transurethral plasmakinetic re-section.One week after the operation,bladder instillation of picibanil was performed on all patients regularly.Then the tumor recurrence rate and complications were observed. Results All opera-tions had succeeded with short average time (30.38±3.2)min,low hemorrhage and no vesical per-foration.After followed up for 6 to 24 months for all patients,the recurence rates was 8%,compli-cation rates was 20%. Conclusions Picibanil is effective and well-tolerated to prevent cancer recur-rence after transurethral plasmakinetic resection of high risk NMIBC.